Cerebral palsy is a lifelong neurodevelopmental condition arising from non-progressive
disorders occurring in the fetal or infant brain. Cerebral palsy has long been categorised into …

The introduction of botulinum toxin more than 25 years ago for the management of
paediatric lower and upper limb hypertonia has been a major advance. BoNT-A as a part of …

Aim To assess the efficacy and safety of repeat abobotulinumtoxinA injections in reducing
upper limb spasticity in children with cerebral palsy (CP). Method This was a double‐blind …

This study was designed to compare the effects of various doses of botulinum neurotoxin A
(BoNT/A) on nerve regeneration. Sixty-five six-week-old rats with sciatic nerve injury were …

Botulinum neurotoxin A (BoNT/A) is categorized as a Tier 1 bioterrorism agent and persists
within muscle neurons for months, causing paralysis. A readily available treatment that …

Despite the frequency of spasticity, robust diagnostic criteria and reliable assessment scales
are required. High-quality studies are needed to support the efficacy of current treatments for …

Abstract Aim This overview of Cochrane systematic reviews (CSRs) reports on current
evidence on the effectiveness of rehabilitation interventions for individuals with cerebral …

Background: Spasticity is a very common neurological sequelae that significantly impacts
the quality of life of patients, affecting more than 12 million people worldwide. Botulinum …

Purpose Intramuscular botulinum toxin A (BTX-A) is used in the management of focal
spasticity in cerebral palsy (CP). The aim was to conduct a systematic review to assess …

Botulinum neurotoxins (BoNT) are the most potent toxins in the world. They are produced by
a few dozens of strains within several clostridial species. The toxin that they produce can …